曲妥珠单抗德鲁替康治疗HER2阳性转移性乳腺癌伴脑转移患者:DESTINY-Breast01亚组分析
DESTINY-Breast01研究评估曲妥珠单抗德鲁替康(T-DXd)在经重度治疗的HER2阳性转移性乳腺癌患者中的疗效,本亚组分析纳入24例有治疗史脑转移患者,确认客观缓解率58.3%,中位无进展生存期18.1个月,8例(47.1%)最佳颅内总体缓解为部分或完全缓解,安全性特征与既往研究一致,作者认为持久临床活性值得进一步研究。
要点
- 脑转移亚组24例,确认客观缓解率58.3%(95%CI 36.6%-77.9%),中位无进展生存期18.1个月(95%CI 6.7-18.1个月)。
- 无脑转移组160例,确认客观缓解率61.3%,中位无进展生存期16.4个月。
- 脑转移组8例(47.1%)最佳颅内总体缓解为部分或完全缓解,7例(41.2%)脑病灶直径最佳变化百分比符合疾病稳定。
核心结论
- T-DXd在有稳定、经治疗脑转移的HER2阳性转移性乳腺癌患者中显示持久疗效,作者认为该人群的持久临床活性值得进一步研究。
研究设计与样本
- DESTINY-Breast01(NCT03248492)评估T-DXd(DS-8201)在经重度治疗的HER2阳性转移性乳腺癌患者中的疗效,本报告为24例有经治疗脑转移史患者的亚组分析。
主要发现
- 脑转移患者确认客观缓解率为58.3%(95%CI 36.6%-77.9%),中位无进展生存期为18.1个月(95%CI 6.7-18.1个月)。
- 无脑转移患者(n=160)确认客观缓解率为61.3%,中位无进展生存期为16.4个月。
- 8例(47.1%)脑转移患者最佳颅内总体缓解为部分缓解或完全缓解,7例(41.2%)脑病灶直径较基线最佳变化百分比符合疾病稳定。
- 2例(8.3%)脑转移患者和2例(1.3%)无脑转移患者出现脑部进展。
- T-DXd安全性特征与既往研究一致。
局限性
- 作者在结论中提出该人群的持久临床活性值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%-77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7-18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation. SIGNIFICANCE: Advances in treating HER2-positive metastatic breast cancer have greatly improved patient outcomes, but intracranial progression remains an important risk for which few therapeutic options are currently available. T-DXd demonstrated durable efficacy in patients with stable, treated BMs. This article is highlighted in the In This Issue feature, p. 2711.
引用
- Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov. 2022. PMID: 36255231. doi:10.1158/2159-8290.CD-22-0837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。